Author/Authors :
Shahverdi, Ehsan Department of Cardiology - Angiology and Sleep Medicine - Bonifatius Hospital Lingen, Lingen, Germany , Karami, Pedram Department of Otorhinolaryngology-Head and Neck Surgery - Rasoul Akram Hospital - Iran University of Medical Sciences, Tehran, Iran , Tavakoli, Farzaneh Hematopoietic Stem Cell Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Maki, Massoumeh Department of Nursing and Midwifery - Falavarjan Branch, Islamic Azad University, Isfahan, Iran , Moazzami, Meysam Department of Pediatrics - Firouzgar Hospital - Iran University of Medical Sciences, Tehran, Iran , Feizi, Fatemeh Department of Laboratory Hematology and Blood Bank - School of Allied Medical Sciences - Shahid Beheshi University of Medical Science, Tehran, Iran , Salamati, Peyman Department of Pediatrics - Tehran University of Medical Sciences, Tehran, Iran , Lotfipour, Alireza Department of Pediatrics - Tehran University of Medical Sciences, Tehran, Iran , Ehsani, Mohammad Ali Department of Pediatrics - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of
lymphoid neoplasms resulting from the proliferation of malignant lymphoid cells.
The aim of this study was to evaluate treatment-related complications in children
with ALL receiving the Medical Research Council (MRC) UKALL X protocol.
Methods: In this retrospective cross-sectional study, children with ALL receiving
the MRC UKALL X protocol from 2008 to 2015 in Bahrami University Hospital,
Iran, were enrolled. The clinical and morphological features were analysed and
treatment-related complications were assessed.
Results: Out of 67 children with ALL receiving the MRC UKALL X protocol, 44
(65.6 %) were boys and 23 (34.4%) were girls. Seven patients (10.7%) relapsed in
the three years of diagnosis, and 50 children (74.6%) had an overall survival of three
years. Average age in three-year-survival group and mortality group was 6.92 (SD:
3.96) and 6.35 (SD: 7.47), respectively (P= 0.38).
Conclusion: Overall survival and relapse rates in this study confirm that this
protocol is an appropriate treatment strategy.
Keywords :
Acute lymphoblastic leukemia (ALL) , Mortality , MRC UKALL X , Neutropenia , Pediatric
